16,160 Shares in Gilead Sciences, Inc. (NASDAQ:GILD) Bought by Maverick Capital Ltd.

Share on StockTwits

Maverick Capital Ltd. acquired a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 16,160 shares of the biopharmaceutical company’s stock, valued at approximately $1,024,000.

Several other large investors also recently modified their holdings of GILD. Nuveen Asset Management LLC raised its holdings in shares of Gilead Sciences by 1,208.1% during the second quarter. Nuveen Asset Management LLC now owns 9,847,359 shares of the biopharmaceutical company’s stock worth $665,288,000 after acquiring an additional 9,094,586 shares during the period. Renaissance Technologies LLC raised its holdings in shares of Gilead Sciences by 56.9% during the second quarter. Renaissance Technologies LLC now owns 12,740,248 shares of the biopharmaceutical company’s stock worth $860,731,000 after acquiring an additional 4,620,000 shares during the period. Invesco Ltd. raised its holdings in shares of Gilead Sciences by 17.5% during the second quarter. Invesco Ltd. now owns 22,975,310 shares of the biopharmaceutical company’s stock worth $1,552,213,000 after acquiring an additional 3,418,193 shares during the period. Marshall Wace North America L.P. raised its holdings in shares of Gilead Sciences by 298.3% during the second quarter. Marshall Wace North America L.P. now owns 3,418,196 shares of the biopharmaceutical company’s stock worth $230,934,000 after acquiring an additional 2,559,972 shares during the period. Finally, First Trust Advisors LP raised its holdings in shares of Gilead Sciences by 77.8% during the second quarter. First Trust Advisors LP now owns 2,825,707 shares of the biopharmaceutical company’s stock worth $190,905,000 after acquiring an additional 1,236,379 shares during the period. Institutional investors and hedge funds own 79.37% of the company’s stock.

In other news, EVP Brett A. Pletcher sold 15,000 shares of Gilead Sciences stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $66.85, for a total value of $1,002,750.00. Following the completion of the transaction, the executive vice president now owns 32,064 shares of the company’s stock, valued at approximately $2,143,478.40. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Brett A. Pletcher sold 4,000 shares of Gilead Sciences stock in a transaction dated Friday, November 1st. The shares were sold at an average price of $64.52, for a total transaction of $258,080.00. Following the completion of the transaction, the executive vice president now directly owns 23,921 shares of the company’s stock, valued at approximately $1,543,382.92. The disclosure for this sale can be found here. In the last three months, insiders sold 36,772 shares of company stock valued at $2,407,737. Insiders own 0.20% of the company’s stock.

A number of equities research analysts recently commented on GILD shares. Maxim Group lowered shares of Gilead Sciences from a “buy” rating to a “hold” rating in a report on Friday, October 25th. Guggenheim set a $86.00 price objective on shares of Gilead Sciences and gave the stock a “buy” rating in a report on Friday, October 25th. ValuEngine upgraded shares of Gilead Sciences from a “sell” rating to a “hold” rating in a report on Wednesday, October 2nd. Morgan Stanley set a $75.00 price objective on shares of Gilead Sciences and gave the stock a “hold” rating in a report on Friday, October 25th. Finally, BidaskClub raised shares of Gilead Sciences from a “sell” rating to a “hold” rating in a research report on Tuesday, October 15th. One equities research analyst has rated the stock with a sell rating, eleven have issued a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $79.09.

Shares of GILD opened at $67.24 on Monday. The firm has a 50-day moving average of $64.90 and a 200-day moving average of $65.29. Gilead Sciences, Inc. has a one year low of $60.32 and a one year high of $72.90. The company has a market cap of $85.07 billion, a PE ratio of 10.93, a price-to-earnings-growth ratio of 3.58 and a beta of 1.14. The company has a debt-to-equity ratio of 1.11, a current ratio of 2.96 and a quick ratio of 2.87.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, October 24th. The biopharmaceutical company reported $1.75 EPS for the quarter, beating analysts’ consensus estimates of $1.74 by $0.01. Gilead Sciences had a net margin of 12.04% and a return on equity of 37.50%. The company had revenue of $5.60 billion during the quarter, compared to the consensus estimate of $5.61 billion. During the same quarter last year, the firm posted $1.84 EPS. The company’s quarterly revenue was up .1% on a year-over-year basis. Analysts expect that Gilead Sciences, Inc. will post 6.64 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 30th. Stockholders of record on Friday, December 13th will be given a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a dividend yield of 3.75%. The ex-dividend date of this dividend is Thursday, December 12th. Gilead Sciences’s dividend payout ratio (DPR) is presently 40.98%.

About Gilead Sciences

Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.

Featured Article: How Short Selling Works

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.